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A study by Zhang et al. in this issue of Neuron reveals a novel mechanism of control of vestibular motor func-
tions by the orexin (hypocretin) system in the perifornical/LH area through the lateral vestibular nucleus in the
brainstem. This knowledge provides new insights into the understanding of brain circuitry that controlsmotor
functions and diseases/conditions related to impairments in this circuitry.The orexin (hypocretin) system in the
lateral hypothalamic (LH)/perifornical area
participates in many critical brain func-
tions including energy and sleep homeo-
stasis, drug addiction, stress response,
and sensorimotor integration (Tsujino
and Sakurai, 2009). It is well established
that the loss of orexin-synthesizing
neurons or orexin receptors leads to
narcolepsy in humans and animals
(Ritchie et al., 2010). Further information
is emerging as to how this loss leads to
the transition from wakefulness to sleep
during an episode of narcolepsy (Ritchie
et al., 2010). However, it is still not known
how the lack of a functioning orexin
system leads to cataplexy or loss of
muscle tone when an episode of narco-
lepsy hits (Scammell et al., 2009).
In an elegant study in this issue of
Neuron, Zhang et al. (2011) demonstrate
an interesting and novel role of the orexin
system in the regulation of motor func-
tions in the brains of rats, which may
help explain the loss of muscle tone (i.e.,
cataplexy) in narcolepsy. The authors
present a convincing case of how the
neuropeptide orexin regulates motor
function through a vestibular center in
the brain, the lateral vestibular nucleus
(LVN) in rats. First, by using quantitative
RT-PCR and immunocytochemistry, the
authors demonstrate the expression of
OX1 and OX2 receptors (hypocretin
receptors 1 and 2) in the LVN, specifically
in the giant Deiters’ neurons in this
nucleus. These results are consistent
with previous reports of the innervation
of the vestibular nuclei in rats by orexin-
containing nerve fibers (Cutler et al.,
1999; Peyron et al., 1998). They then588 Neuron 69, February 24, 2011 ª2011 Elsinvestigated the effects of orexin on the
activity of LVN neurons (putative Deiters’
neurons according to their morphological
and electrophysiological properties) in
brainstem slices, a standard method of
examining the cellular mechanisms that
underlie behavioral phenotypes in
rodents. Their results indicate that in an
overwhelming majority (>90%) of tested
neurons, orexin-A (hypocretin-1) induced
an inward (excitatory) current under
voltage-clamp in a dose-dependent way.
The orexin-A-induced inward current
was partially blocked by a selective
orexin-A receptor antagonist, SB334867.
Orexin-B (hypocretin-2) and a selec-
tive orexin-B receptor agonist, [Ala11,
D-Leu15]-orexin-B, induced similar effects
in these neurons as well. These results
convincingly demonstrate that both
orexin-A and B receptors are responsible
for the inward current in LVN neurons.
The authors further show that the
closure of the inwardly rectifier potassium
(Kir) channels and activation of Na+-Ca2+
exchangers are responsible for the inward
current induced by orexin-A. This was re-
vealed by examining the current-voltage
relationship and using blockers of Kir
channels and Na+-Ca2+ exchangers.
These data are consistent with reports of
direct excitatory effects of orexin on post-
synaptic neurons in other brain areas
(Wu et al., 2002, 2004). The consequence
of the inward current on LVN neurons is to
directly excite them. The application of
orexin-A induced a significant depolariza-
tion and increase in the firing rate of the
LVN neurons. Orexin-A facilitated the
generation of action potentials (APs) by
reducing the latency of induction of APsevier Inc.and increasing the instantaneous firing
rate. Based on these cellular studies, the
authors reasoned that orexin fibers that
innervate the LVN should exert physiolog-
ical functions in the regulation of vestib-
ular motor behaviors.
A remarkable array of in vivo electro-
physiological and behavioral testing
was then designed to examine this
hypothesis: first, in urethane-anesthe-
tized rats, a microinjection of orexin-A
into the LVN excited LVN neurons with
a short latency. Next, rats given a unilat-
eral microinjection of orexin-A into the
LVN showed a significant increase in the
rotation to the contralateral direction of
the injection side as compared with rats
that received vehicle injection or those
that were sham operated upon, suggest-
ing that infusion of orexin-A into the LVN
induces changes in static posture. In
addition, bilateral infusion of orexin-A
into the LVN significantly reduced the
traverse time in the horizontal balance
beam test and the time required for rats
to turn 180 to an upward position from
the initial downward position in the
negative geotaxis test, suggesting that
the application of orexin into the LVN
promotes dynamic postural changes in
animals. Finally and most intriguingly,
the infusion of orexin-A receptor antago-
nist SB334867 neither inhibited basal
firing of LVN neurons nor blocked rat
motor performance in either the horizontal
balance beam or negative geotaxis
tests. Rather, this treatment significantly
compromised behaviors depending on
the motor challenge. In rats treated with
SB334867, the time required to traverse
an inclined balance beam significantly
Figure 1. Diagram Showing the Orexinergic Innervation of the LVN
The solid line indicates the direct projection of orexin-containing fibers to the
LVN. The gray line indicates pathways from the LVN to the LHA, which may
be mediated by polysynaptic mechanisms (Katafuchi et al., 1987). LHA, lateral
hypothalamic area; LVN, lateral vestibular nucleus; 3V, the third ventricle; 4V,
the fourth ventricle.
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Previewsincreased as compared with
sham or vehicle groups. In
an accelerating rota-rod test,
the infusion significantly de-
creased the time that rats
stayed on the accelerating
rota-rod. These data indicate
that endogenous orexin is
required in the central control
of motor functions in animals.
All together, the results pre-
sented in this study are clear-
cut and self-evident but
leave some unanswered
questions. For instance, it is
not clear why the orexin-A re-
ceptor antagonist SB334867
induced such significantef-
fects in behavioral testing,
but why only partial inhibition
of orexin-A-induced effects
in LVN neurons in brain slices.
This discrepancy may be
due to differential effects ofSB334867 under in vitro versus in vivo
conditions. It is not shown whether LVN
neurons were in fact activated by the
microinjection of orexin-A into the LVN.
Except for the readout of behavioral
changes, no other evidence was provided
in the same experiments that would indi-
cate the activation of LVN neurons (e.g.,
the detection of c-fos expression) by
orexin-A. And related to this question, it
is not clear to what extent the inhibition
of LVN neurons by SB334867 can lead to
the alterations inmotor functions reported
in these animals. Also, this study does not
address whether changes occur in the
levels of orexin in the LVN during the
time that the motor functions were re-
ported to be compromised. The tech-
niques required to answer thesequestions
are currently available and could be em-
ployed in future studies by these authors
or other investigators in the field.
Nevertheless, this study has broad
implications regarding the role of the
orexin system in the brain under physio-
logical and pathological conditions. First,
these experiments confirm the innerva-
tion of the LVN by the orexin system in
the LH/periforncal area, specifically to
the critical neurons in the LVN that are
responsible for the control of posture
and motor function proposed by previous
studies (Cutler et al., 1999; Peyron et al.,
1998) (Figure 1). More importantly, thisstudy provides a novel and crucial piece
of evidence to demonstrate the role of
this projection in the central control of
motor functions. Second, although the
authors suggest that their results demon-
strate a role of orexin in the control of
motor functions independent of its role in
promoting wakefulness and arousal, the
effects of orexin on neurons in the LVN
can still account for compromised vestib-
ular motor functions resulting from insuffi-
cient arousal in animals. Third, the most
important implication of these findings is
that orexin-mediated effects on LVN
neurons may not play a substantial role
in static or basal motor control, but rather
may participate in motor control under
substantial motor challenge. The link
between the loss of function of the orexin
system and narcolepsy is established
(Ritchie et al., 2010); however, it still
remains to be determined how this loss
leads to cataplexy (Scammell et al.,
2009). Although the animal models used
here are not intended for the study of
cataplexy (nor did the loss of motor
function or blockade of orexin-mediated
effects in the LVN lead to any loss of
motor functions similar to cataplexy),
this study in its own right may provide
a novel view of how impairment of the
output from the orexin system leads
to cataplexy in diseases and conditions
such as narcolepsy.Neuron 69, February 24,In summary, there is still
a distance to go to identify
how the loss of orexin-medi-
ated functions leads to cata-
plexy, but this study certainly
provides new promise toward
that end. Several lines of
inquiry can be explored.
First, to pinpoint the role of
the orexin system in motor
control mediated by the LVN
neurons, it is essential to
monitor the activity levels of
orexin neurons as these
changes in motor functions
occur in various animal
models including those used
in this study. Conversely, it is
critical to examine whether
the direct activation or
silencing of orexin neurons
in vivo with optogenetic ap-
proaches such as photosti-
mulation with channelrho-dopsin-2 (Adamantidis et al., 2007) leads
to initiation or interruption of changes in
motor functions mediated by the LVN
neurons. Next, if the effects mediated by
orexin underlie the cataplexy resulting
from the loss of function of the orexin
system as suggested by this study, it is
both essential and intriguing to know
whether the mechanisms reported here
exist in other brain areas that control
motor functions and sensorimotor inte-
gration such as the basal ganglia,
spinal locomotor circuitry, and so on
(El Manira and Kyriakatos, 2010). Since
the blockade of orexin-mediated effects
in a single area may lead to just attenua-
tion and not complete loss of motor
control as reported here, a prospective
study combining multiple brain regions
to reveal the role of orexin in cataplexy
would be very beneficial. Lastly, it is
important to examine the circuitry investi-
gated in this report in animal models of
cataplexy and particularly in animals
given an infusion of orexin into the LVN
or other brain areas to determine if this
treatment can rescue or improve the
symptoms of cataplexy.REFERENCES
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